CAMK2G and myocardial infarction: Recently, NP202, a natural product and prodrug with moderate in vitro CaMKII inhibitory activity (IC50 of 250 nM) (174), failed to substantially affect left ventricular remodeling in patients presenting with myocardial infarction (175).